Zevalin safe and effective for non-Hogdkin's lymphoma patients with advanced disease
ORLANDO, May 17 According to a University of Pittsburgh Medical Center (UPMC) study, patients with advanced non-Hodgkin's lymphoma (NHL) previously treated with chemotherapy and adult stem cell transplantation can safely tolerate Zevalin (ibritumomab tiuxetan), a radiolabeled monoclonal antibody that targets radiation directly to a tumor. The study, presented at the 41st annual meeting of the A...